SCHEMBL5765022

SCHEMBL5765022

O=C(CCCl)Oc1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
KMT2A Q03164 9/20 0.50
ALDH1A1 P00352 3/20 0.50
HSD17B10 Q99714 2/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
BCL9 O00512 1/20 0.40
CTNNB1 P35222 1/20 0.40
ATM Q13315 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
HPGD P15428 1/20 0.39
FAAH O00519 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ESR1 P03372 1/20 0.38
RECQL P46063 1/20 0.38
HIF1A Q16665 1/20 0.38
NR4A2 P43354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23027523 0.89 KMT2A (0.55) SMN1; SMN2KMT2AALDH1A1HSD17B10LMNA
SCHEMBL29279079 0.88 KMT2A (0.63) SMN1; SMN2KMT2AALDH1A1HSD17B10LMNA
SCHEMBL7736863 0.84 KMT2A (0.60) SMN1; SMN2KMT2AALDH1A1HSD17B10LMNA
SCHEMBL11229152 0.84 KMT2A (0.53) SMN1; SMN2KMT2AALDH1A1HSD17B10LMNA
SCHEMBL4641736 0.82 KMT2A (0.52) SMN1; SMN2KMT2AALDH1A1HSD17B10LMNA
SCHEMBL28987103 0.82 KMT2A (0.59) SMN1; SMN2KMT2AALDH1A1HSD17B10LMNA
SCHEMBL1970906 0.82 KMT2A (0.59) SMN1; SMN2KMT2AALDH1A1HSD17B10LMNA
SCHEMBL4642418 0.81 KMT2A (0.60) SMN1; SMN2KMT2AALDH1A1HSD17B10LMNA
SCHEMBL4642464 0.81 KMT2A (0.50) SMN1; SMN2KMT2AALDH1A1HSD17B10LMNA
SCHEMBL6740542 0.81 KMT2A (0.58) KMT2AALDH1A1HSD17B10LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4660185-A1 NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS Eurofarma Laboratórios S.A. (BR) 2025-12-10 EP disclosed
WO-2024159288-A1 NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2024-08-08 WO disclosed
CN-112955436-B 6-oxo-1, 6-dihydropyridazine derivatives, preparation method and application thereof in medicines 福建盛迪医药有限公司 2023-08-11 CN disclosed
US-20220073471-A1 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO (CN) 2022-03-10 US disclosed
EP-3907218-A1 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2021-11-10 EP disclosed
WO-2020140959-A1 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2020-07-09 WO disclosed
CN-1860112-A 3-amino chroman and 2-amino tetralin derivatives WYETH CORP (US) 2006-11-08 CN disclosed
EP-1651637-A1 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES Wyeth (US) 2006-05-03 EP disclosed
US-20050032873-A1 3-Amino chroman and 2-amino tetralin derivatives WYETH (US) 2005-02-10 US disclosed
WO-2005012291-A1 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES WYETH (US) 2005-02-10 WO disclosed
EP-0225217-A1 2-(3-Chloro-propionyl)-4-fluorophenol, process for its preparation and its use in the preparation of 6-fluorochroman-4-on ISOCHEM (FR) 1987-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073471-A1 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF CACNA1D, CACNA1F, CACNA1B SMN1; SMN2 3019/4885KMT2A 3688/4885ALDH1A1 268/4885
US-20050032873-A1 3-Amino chroman and 2-amino tetralin derivatives TPH2, HTR2C, HTR7 SMN1; SMN2 2258/4885KMT2A 1963/4885ALDH1A1 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.